Cookie Preferences
By clicking “Accept All”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage and assist in our marketing efforts as outlined in our cookie policy.
Strictly Necessary (Always Active)
Cookies required to enable basic website functionality.
Cookies helping us understand how this website performs, how visitors interact with the site, and whether there may be technical issues.
Cookies used to deliver advertising that is more relevant to you and your interests.
Cookies allowing the website to remember choices you make (such as your user name, language, or the region you are in).

Ventures

Invest in breakthrough healthtech solutions that transform patients' lives.

00:00
/
00:00
00:00
/
00:00
Invest in transformative health innovations
Invest in transformative health innovations

We vet over 1500 innovations yearly and identify, build, and invest in 20 to 25 ventures that address crucial, unmet needs in the healthcare sector. Our ventures lead in areas such as personalized medicine, AI diagnostics, and medical devices, all of which show substantial potential for growth, return, and impact.

00:00
/
00:00
00:00
/
00:00
Invest alongside NLC
Invest alongside NLC

As an investor in an NLC venture, you always invest alongside NLC. Our team of 80+ experts offers comprehensive support to our ventures, including regulatory guidance, product development assistance, and clinical trial setup. This extensive, tailored support system de-risks your investment and enhances the likelihood of venture success. Single-company investments start at €25K.

00:00
/
00:00
00:00
/
00:00
Invest with impact
Invest with impact

By investing in one of our ventures, you help bring transformative health solutions to patients in need, directly impacting their lives. NLC is a certified B Corp and supports UN Sustainable Development Goals 3, 9, and 17, our funds are SDFR-9 compliant, which means we adhere to the strictest impact regulations. Investing in NLC ventures can be your pathway to high-impact capital deployment.

Receive the latest investment opportunities that match your interests, directly in your inbox. Stay informed and never miss out.

a highlight from our portfolio

Angiogenesis Analytics

Angiogenesis Analytics

Angiogenesis Analytics is transforming prostate cancer diagnosis by integrating artificial intelligence with advanced ultrasound technology. Our mission is to make the detection of prostate cancer quicker, more affordable, and significantly less invasive than traditional methods. By pioneering the innovative PCAVision technology, we are setting new standards in healthcare.
Visit website
Download documents
PEP Health

PEP Health

PEP Health is revolutionizing how healthcare providers understand and improve patient experiences by leveraging machine-learning technology to give healthcare organizations, regulators, and insurers the real-time, actionable insights they need to have a direct and dramatic impact on patient experiences.
Visit website
Download documents
Charm
Empowering low-resource healthcare professionals around the world

ChARM, or the Children’s Automated Respiration Monitor, addresses the challenge of pneumonia misdiagnosis in low-resource settings. This battery-powered device provides accurate breathing rate monitoring for children under five, empowering healthcare workers to make correct diagnoses swiftly. By streamlining the diagnostic process, ChARM facilitates timely treatment, potentially saving thousands of young lives annually.

Active
🇳🇱 Netherlands
Charm
Amotio
Easier joint implant revision surgery through 3D technology

Amotio addresses the challenge of revision surgeries for hip, knee, and shoulder implants with their innovative approach. Collaborating with expert revision surgeons and guided by NLC, they offer a patented solution for improved implant revision surgery. By developing unique bone cement removal devices and integrating advanced patient-specific 3D surgical planning and printing technology, Amotio aims to set a new standard for excellence in these surgeries. Their goal is to reduce complexity, trauma, and recovery time while cutting costs for healthcare providers.

Active
🇳🇱 Netherlands
Amotio
Liftya
Unique personalized shoulder assisting device

Introducing Liftya, a solution for shoulder instability. Developed with a patented spherical hinge mechanism, Liftya mimics the natural shoulder joint movement, offering stability and full range of motion. Unlike traditional braces, Liftya promotes motor recovery and independence, reducing pain and healthcare costs for patients.

Active
🇳🇱 Netherlands
Liftya
Foveo FERTILITY
Enhancing assisted fertility through optimal environment control

Foveo Fertility addresses the challenge of improving in vitro fertilization (IVF) success rates by providing a stable physiological environment for egg cells. Unlike current methods that expose egg cells to air, leading to cooling and evaporation, Foveo Fertility ensures consistent conditions for optimal egg cell quality. This innovation also streamlines workflow in the IVF lab, reducing human error and saving time for embryologists. With no other product on the market offering constant physiological conditions for egg cells, Foveo Fertility aims to improve the lives of both lab workers and patients by maximizing the potential for successful pregnancies.

Active
🇬🇧 United Kingdom
Foveo FERTILITY
Retinacheck
Using retinal images for diabetic retinopathy

Retinacheck addresses the challenge of Diabetic Retinopathy, the leading cause of blindness in working-age adults, particularly in regions with poor access to eye care. With over 23% of China's 110 million diabetics affected, Retinacheck's solution becomes crucial. By utilizing retinal images captured by a fundus camera, their Convolutional Neural Network algorithm can diagnose Diabetic Retinopathy with over 94% accuracy, surpassing traditional methods.

Exited
🇳🇱 Netherlands
Retinacheck
Larynxlock
Solution to prevent laryngeal air leaks during surgery

Introducing LarynxLock, prevents air leaks during surgery with a gentle pressure on the mouth's base, ensuring patients receive uninterrupted air supply. LarynxLock not only safeguards patients from complications but also reduces physical strain and surgery duration, offering a smart and cost-effective solution for improved surgical outcomes.

Active
🇳🇱 Netherlands
Larynxlock
Occlunova
An implantable device for people with chronic atrial fibrillation (AF)

OCCLUNOVA introduces a novel solution for chronic atrial fibrillation (AF), a condition affecting millions worldwide where the heart's upper chambers beat irregularly. Their implantable device aims to prevent strokes associated with AF by sealing off the left atrial appendage (LAA), where blood clots often form. Unlike traditional methods, which can cause complications due to their rigid frame, OccluNova's design uses a flexible balloon to fully seal the LAA. This innovative approach minimizes risks like pericardial effusions and incomplete closure, offering a safer option for AF patients.

Active
🇺🇸 United States of America
Occlunova
Altach
Off-the-shelf solution for improved cartilage repair

Altach is tackling the challenge of treating damaged cartilage effectively without costly or complex procedures. Altach's solution is a simple, ready-to-use implant that makes microfracture treatment better. It's made from cartilage-like material and helps the body build new, healthy cartilage. This means fewer surgeries and better outcomes for patients.

Active
🇮🇪 Ireland
Altach

Our impact

15
Countries active in
2.4M
Patients impacted
20-25
Ventures built annually
40+
Healthcare experts
70+
Active ventures in our portfolio
€160M+
Raised by NLC ventures

Explore our 2024 Impact report

Woman with hands in the air in nature
Maurits Schouten
00:00
/
00:00
I consider the medical sector to be very attractive. However, without the right expertise, network, and diversification, the risks can be significant. NLC removes these barriers and creates an attractive opportunity for me to participate as an investor in this sector.
Maurits Schouten

Maurits Schouten

Impact investor and Board Member of PYM

Peter Veldman
00:00
/
00:00
What I really like about NLC and what triggered my investment in the company is the strong culture and the quality of the team. NLC is able to de-risk the innovation cycle by building ventures at scale, thereby playing a leading role in shaping the future of healthcare.
Peter Veldman

Peter Veldman

Advisor and previous Deputy Head of Fund Operations at EQT Group

Invest in a portfolio of companies

A formal clothed man on a bridge in the city

Create a healthier future with us

Lars Olthof
Head of Venture Finance, Venture Investment Director